SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for SAB Biotherapeutics in a note issued to investors on Tuesday, July 22nd. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.07) per share for the quarter, up from their previous estimate of ($0.44). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.19) EPS, FY2027 earnings at ($0.22) EPS, FY2028 earnings at ($0.28) EPS and FY2029 earnings at ($0.28) EPS. \n\nSAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.44. \n\nSeparately, Chardan Capital reissued a “buy” rating and issued a $20.00 target price on shares of SAB Biotherapeutics in a report on Thursday, May 15th. \n\nSAB Biotherapeutics stock opened at $2.60 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.69 and a current ratio of 1.69. The firm has a market capitalization of $24.15 million, a price-to-earnings ratio of -0.70 and a beta of 0.52. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60. The stock’s fifty day moving average is $2.01 and its two-hundred day moving average is $1.99. \n\nLarge investors have recently made changes to their positions in the stock. Northern Trust Corp acquired a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at $43,000. Geode Capital Management LLC boosted its stake in shares of SAB Biotherapeutics by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after acquiring an additional 12,692 shares during the last quarter. Diadema Partners LP acquired a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at $114,000. Silver Oak Securities Incorporated acquired a new stake in shares of SAB Biotherapeutics during the first quarter valued at $30,000. Finally, HB Wealth Management LLC boosted its stake in shares of SAB Biotherapeutics by 10.9% during the first quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock valued at $358,000 after acquiring an additional 25,800 shares during the last quarter. Institutional investors and hedge funds own 7.82% of the company’s stock. \n\nSAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for SAB...

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw updated earnings estimates from HC Wainwright, which raised its Q3 2025 EPS forecast from -$0.44 to -$0.07. The company reported Q2 earnings of -$0.56, beating the consensus estimate of -$1.00. Chardan Capital reissued a 'Buy' rating with a $20.00 target price. The firm has a market cap of $24.15M, a P/E ratio of -0.70, and institutional ownership of 7.82%.